Oncology firm Concerto HealthAI , which provides Real-World Data and enterprise Artificial Intelligence tech solutions, raised $150 million in its latest funding round.
The Series B round was led by Declaration Partners, with participation from Maverick Ventures, SymphonyAI Group, and AllianceBernstien PCI. The funding will support the company’s continued innovation in RWD and technology products and services for commercial patient solutions, regulatory and non-regulatory applications, and adjacent therapy expansion.
Concerto HealthAI added new members to its board of directors thanks to this transaction. Joining the board are Andrew Goldfarb, partner at Declaration Partners, and Leif Pedersen, senior operating partner at SymphonyAI Group.
“The significant commitment and life sciences expertise of our investors validates and accelerates our strategy,” said Jeff Elton, PhD, CEO of Concerto HealthAI, in a statement. “This investment underscores the amazing team and talent we have brought together with a common purpose of advancing Precision Oncology solutions for the most devastating cancers based on our engineered RWD, AI-enabled technologies, and advanced scientific services.”
Concerto Health AI aims to unite unique data assets, leading AI-based technologies, and key outcomes research and data science talent, to revolutionize clinical and outcomes research to accelerate the insights benefiting patient treatment.